XML 52 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Equity (Tables)
 3 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Schedule of stock based compensation expense Share-based compensation expense was as follows:
Three Months Ended March 31,
20252024
Stock options:
Pre-tax compensation expense$1 $2 
Income tax benefit— — 
Stock option expense, net of income taxes1 2 
Restricted stock units (“RSUs”):
Pre-tax compensation expense7 7 
Income tax benefit(1)(1)
RSUs, net of income taxes6 6 
Performance shares and other share-based awards:
Pre-tax compensation expense5 4 
Income tax benefit— — 
Performance shares and other share-based compensation expense, net of income taxes5 4 
Total share-based compensation:
Pre-tax compensation expense13 13 
Income tax benefit(1)(1)
Total share-based compensation expense, net of income taxes$12 $12 
Schedule of valuation assumptions for stock options We estimated the fair value of each option grant by using the Black-Scholes option-pricing model with the following assumptions:
Three Months Ended March 31,
20252024
Expected life (in years)5.55.5
Risk-free interest rate4.1%4.2%
Expected volatility28.2%28.1%
Expected dividend yield2.5%2.9%
Schedule of stock option transactions
Stock option activity for 2025 was as follows:
Number of Options
(in thousands)		Weighted Average Exercise Price per ShareAverage Remaining Contractual Term (in years)Aggregate Intrinsic Value
(in millions)
Outstanding as of December 31, 20241,453$100.04 5.6$55 
Granted158130.57 
Exercised(16)94.22 
Cancelled—— 
Outstanding as of March 31, 20251,595$103.12 5.8$52 
Exercisable as of March 31, 20251,271$99.43 5.0$46 
Schedule of additional information pertaining to stock option activity
Additional information pertaining to stock option activity was as follows:
Three Months Ended March 31,
20252024
Weighted average grant date fair value of stock options granted (per share)$33.53 $26.33 
Total intrinsic value of stock options exercised1 5 
Schedule of restricted unit activity
RSU activity for 2025 was as follows:
Number of
Restricted
Shares
(in thousands)		Weighted
Average
Fair Value
per Share
Non-vested as of December 31, 2024538$99.58 
Granted163130.57 
Vested(157)88.94 
Cancelled(3)101.52 
Non-vested as of March 31, 2025541$111.81 
Summary of net changes in accumulated other comprehensive loss A summary of accumulated other comprehensive loss for 2025 and 2024 was as follows:
Cumulative Translation AdjustmentHedging ActivitiesPension and Postretirement AdjustmentAOCL
Balance as of December 31, 2024$(1,061)$4 $(29)$(1,086)
Other comprehensive income before reclassification adjustments 50 17 — 67 
(Income) reclassified from AOCL— (2)— (2)
Tax (provision)— (4)— (4)
Net other comprehensive income50 11 — 61 
Balance as of March 31, 2025$(1,011)$15 $(29)$(1,025)
Cumulative Translation AdjustmentHedging ActivitiesPension and Postretirement AdjustmentAOCL
Balance as of December 31, 2023$(961)$(48)$(47)$(1,056)
Other comprehensive (loss) before reclassification adjustments — (41)— (41)
Loss reclassified from AOCL— 33 1 34 
Tax benefit— 1 — 1 
Net other comprehensive (loss) income— (7)1 (6)
Balance as of March 31, 2024$(961)$(55)$(46)$(1,062)
Schedule of basic and diluted earnings per common share The following table presents information about the computation of basic and diluted earnings per common share (“EPS”):
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
Net Income
Attributable
to Ingredion		Weighted
Average
Shares		Per
Share
Amount		Net Income
Attributable
to Ingredion		Weighted
Average
Shares		Per
Share
Amount
Basic EPS$197 64.5$3.05 $216 65.7$3.29 
Effect of Dilutive Securities (i)
1.11.1
Diluted EPS$197 65.6$3.00 $216 66.8$3.23 
_____________________
(i)Incremental shares from assumed exercise of dilutive stock options, vesting of dilutive stock options, vesting of dilutive RSUs and other awards.